The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer
Open accessAbstract
Chemotherapy remains the preferred choice of treatment for prostate cancer but modest drug response and significant toxicity by conventional methods of administration limit their efficacy. In our study, we determined the efficacy of paclitaxel (Tx)‐loaded biodegradable nanoparticles (NPs) on tumor inhibition. We hypothesized that NPs following conjugation to transferrin (Tf) ligand (NPs‐Tf) would enhance the therapeutic efficacy of the encapsulated drug. The antiproliferative activity of NPs was determined in human prostate cancer cell line (PC3) and their effect on tumor inhibition in a murine model of prostate cancer. NPs (∼ 220 nm in diameter, 5.4% w/w drug loading) under in vitro conditions exhibited sustained release of the encapsulated drug (60% release in 60 days). The IC 50 (concentration of drug for 50% inhibition of cell growth) of the drug with Tf‐conjugated NPs (Tx‐NPs‐Tf) was about 5‐fold lower than that with unconjugated NPs (Tx‐NPs) or drug in solution. Animals that received a single‐dose intratumoral injection of Tx‐NPs‐Tf (Tx dose = 24 mg/kg) demonstrated complete tumor regression and greater survival rate than those that received either Tx‐NPs or Tx‐Cremophor® EL formulation. In conclusion, sustained release NPs demonstrated greater antitumor activity following their conjugation to Tf ligand. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Self-citationNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Panyam, J., Zhou, W., Prabha, S., Sahoo, S. K., & Labhasetwar, V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0088com · Cited by 1,044
Self-citationTargeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 990
Self-citationMu, L., & Feng, S. S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00320-6 · Cited by 725
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs
Torchilin, V. P., Lukyanov, A. N., Gao, Z., & Papahadjopoulos-Sternberg, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931428100 · Cited by 538
Cited by
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging
Parveen, S., Misra, R., & Sahoo, S. K. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.05.016 · Cited by 1,436
Self-citationNicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
In Vitro Cytotoxicity of Nanoparticles in Mammalian Germline Stem Cells
Braydich-Stolle, L., Hussain, S., Schlager, J. J., & Hofmann, M.-C. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi256 · Cited by 1,247
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Self-citationThe transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Mohanty, C., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.062 · Cited by 530
Self-citationBiodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Self-citationThe transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Transferrin: structure, function and potential therapeutic actions
Gomme, P. T., McCann, K. B., & Bertolini, J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03333-1 · Cited by 480
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals
Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., Men, Y., Zhang, Y., Li, R.-J., Yang, T.-Y., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.020 · Cited by 447
Polymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860701794353 · Cited by 427
Self-citationCancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy
Chaturvedi, V. K., Singh, A., Singh, V. K., & Singh, M. P. (2019) · Current Drug Metabolism · doi:10.2174/1389200219666180918111528 · Cited by 418
Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy
Dilnawaz, F., Singh, A., Mohanty, C., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.057 · Cited by 385
Self-citationReddy, N. J., Nagoor Vali, D., Rani, M., & Rani, S. S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2013.08.039 · Cited by 379
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340
Self-citationTargeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Acharya, S., Dilnawaz, F., & Sahoo, S. K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.008 · Cited by 333
Self-citationTargeted Drug Delivery in Cancer Therapy
Vasir, J. K., & Labhasetwar, V. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400405 · Cited by 327
Self-citationJoralemon, M. J., O'Reilly, R. K., Hawker, C. J., & Wooley, K. L. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053919x · Cited by 319
TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs
Rao, K. S., Reddy, M. K., Horning, J. L., & Labhasetwar, V. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.08.004 · Cited by 314
Self-citationTransferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery
Parveen, S., & Sahoo, S. K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.023 · Cited by 302
Self-citationNanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2017.11.003 · Cited by 288
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
Jin, S., & Ye, K. (2007) · Biotechnology Progress · doi:10.1021/bp060348j · Cited by 283
Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier
Chang, J., Jallouli, Y., Kroubi, M., Yuan, X.-B., Feng, W., Kang, C.-S., Pu, P.-Y., & Betbeder, D. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.035 · Cited by 278
Cho, H.-S., Dong, Z., Pauletti, G. M., Zhang, J., Xu, H., Gu, H., Wang, L., Ewing, R. C., Huth, C., Wang, F., et al. (2010) · ACS Nano · doi:10.1021/nn101000e · Cited by 265
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery
Patil, Y. B., Toti, U. S., Khdair, A., Ma, L., & Panyam, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.056 · Cited by 242
Shen, H., Hong, S., Prud’homme, R. K., & Liu, Y. (2011) · Journal of Nanoparticle Research · doi:10.1007/s11051-011-0354-7 · Cited by 120
Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages
Almouazen, E., Bourgeois, S., Boussaïd, A., Valot, P., Malleval, C., Fessi, H., Nataf, S., & Briançon, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.025 · Cited by 47
Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., & Leung, H. Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0681-5 · Cited by 42
Metadata
- Authors
- Sahoo, S. K., Ma, W., & Labhasetwar, V.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-08-17
- Volume
- 112
- Issue
- 2
- Pages
- 335-340
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1999204999
- Cited by
- 327
- References
- 35
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.